Competitive enzyme inhibition defined

Alternatively we could measure the 1C50 or the Ki (inhibitory constant) for the perpetrator. The A) of a perpetrator that is capable of inhibiting an enzyme (or transporter) is the dissociation constant for the enzyme-inhibitor complex. Accurate estimation of the A) requires, among other things, the appropriate definition or specification of the type of enzyme inhibition (e.g., competitive, noncompetitive, or uncompetitive). The appropriate in vitro experiments require that multiple concentrations of the inhibitor must be used as well as a range of substrate concentrations that embrace the substrate Km, and from these experiments both the type of inhibition elicited by the perpetrator can be deduced and the A) value for the perpetrator can be estimated. The Ki will have units of concentration. Alternatively, K values can be computed from /C50 values for an inhibitor. The /C50 is defined simply as the inhibitor concentration that decreases the biotransformation of a substrate at a single, specified concentration by 50%. This parameter obviously also has units of concentration (e.g., pM), and can be related to the Ki as follows. 

One of the ways of altering enzyme activity is through compounds binding in the active site. If these compounds are not part of the normal reaction, they inhibit the enzyme. An inhibitor of an enzyme is defined as a compound that decreases the velocity of the reaction by binding to the enzyme. It is a reversible inhibitor if it is not covalently bound to the enzyme and can dissociate at a significant rate. Reversible inhibitors are generally classified as competitive, noncompetitive, or uncompetitive with respect to their relationship to a substrate of the enzyme. In most reactions, the products of the reaction are reversible inhibitors of the enzyme producing them. 

In such inhibition, the inhibitor and die substrate can simultaneously bind to the enzyme. The nature of the enzyme-inhibitor-substrate binding has resulted in a ternary complex defined as EIS. The Ks and Kt are identical to the corresponding dissociation constants. It is also assumed that the EIS does not react further and is unable to deliver any product P. The rate equation for non-competitive inhibition, unvAX, is influenced ... 

In this scheme, EOH is the enzyme, IX is the inhibitor (either a carbamate or an organophosphate). EOH(IX) is analogous to the Michaelis Menton comploc seen with the substrate reaction. EOI is the acyl-enzyme intermediate for carbamates or a phosphoro-enzyme intermediate for the organophosphates. The equilibrium constant for this reaction (K ) is defined as k /k and the phosphorylation or carbamylation constant is defined as k2- In this study 42)y ANTX-A(S) was found to be more specific for AChE than BUChE. The double reciprocal and Dixon plot of the inhibition of electric eel AChE indicated that the toxin is a non-competitive inhibitor decreases, k remains unchanged) (Figure 2). 

In this chapter we described the thermodynamics of enzyme-inhibitor interactions and defined three potential modes of reversible binding of inhibitors to enzyme molecules. Competitive inhibitors bind to the free enzyme form in direct competition with substrate molecules. Noncompetitive inhibitors bind to both the free enzyme and to the ES complex or subsequent enzyme forms that are populated during catalysis. Uncompetitive inhibitors bind exclusively to the ES complex or to subsequent enzyme forms. We saw that one can distinguish among these inhibition modes by their effects on the apparent values of the steady state kinetic parameters Umax, Km, and VmdX/KM. We further saw that for bisubstrate reactions, the inhibition modality depends on the reaction mechanism used by the enzyme. Finally, we described how one may use the dissociation constant for inhibition (Kh o.K or both) to best evaluate the relative affinity of different inhibitors for ones target enzyme, and thus drive compound optimization through medicinal chemistry efforts. 

As discussed above, the degree of inhibition is indicated by the ratio of k3/k and defines an inhibitor constant (Kj) [Eq. (3.19)], whose value reports the dissociation of the enzyme-inhibitor complex (El) [Eq. (3.20)]. Deriving the equation for competitive inhibition under steady-state conditions leads to Eq. (3.21). Reciprocal plots of 1/v versus 1/5 (Lineweaver-Burk plots) as a function of various inhibitor concentrations readily reveal competitive inhibition and define their characteristic properties (Fig. 3.5). Notice that Vmax does not change. Irrespective of how much competitive inhibitor is present, its effect can be overcome by adding a sufficient amount of substrate, i.e., substrate can be added until Vmax is reached. Also notice that K i does change with inhibitor concentration therefore the Km that is measured in the presence of inhibitor is an apparent Km- The true KM can only be obtained in the absence of inhibitor. 

The analysis of fish tissues for ciguatoxin by a newly developed enzyme-immunoassay procedure (26, 27) has been carried out in this study. Three areas of examinations have been attempted (1) the examination of clinically defined and documented and non-toxic consumed fish samples (2) the assessment of freshly caught fishes from the sites in the Leeward part of the island of Oahu where ciguatoxin is found and (3) competitive inhibition with suspension of purified ciguatoxin and closely related structurally similar polyether toxins. 

Two other types of reversible inhibition, uncompetitive and mixed, though often defined in terms of one-substrate enzymes, are in practice observed only with enzymes having two or more substrates. An uncompetitive inhibitor (Fig. 6-15b) binds at a site distinct from the substrate active site and, unlike a competitive inhibitor, binds only to the ES complex. In the presence of an uncompetitive inhibitor, the Michaelis-Menten equation is altered to... 

The systems described in this chapter possess properties that define supramolecular reactivity and catalysis substrate recognition, reaction within the supermolecule, rate acceleration, inhibition by competitively bound species, structural and chiral selectivity, and catalytic turnover. Many other types of processes may be imagined. In particular, the transacylation reactions mentioned above operate on activated esters as substrates, but the hydrolysis of unactivated esters and especially of amides under biological conditions, presents a challenge [5.77] that chemistry has met in enzymes but not yet in abiotic supramolecular catalysts. However, metal complexes have been found to activate markedly amide hydrolysis [5.48, 5.58a]. Of great interest is the development of supramolecular catalysts performing synthetic... 

Over the past decade there has been a substantial improvement in the ability to predict metabolism-based in vivo drug interactions from kinetic data obtained in vitro. This advance has been most evident for interactions that occur at the level of cytochrome P450 (CYP)-catalyzed oxidation and reflects the availability of human tissue samples, cDNA-expressed CYPs, and well-defined substrates and inhibitors of individual enzymes. The most common paradigm in the prediction of in vivo drug interactions has been first to determine the enzyme selectivity of a suspected inhibitor and subsequently to estimate the constant that quantifies the potency of reversible inhibition in vitro. This approach has been successful in identifying clinically important potent competitive inhibitors, such as quinidine, fluoxetine, and itraconazole. However, there is a continuing concern that a number of well-established and clinically important CYP-mediated drug interactions are not predictable from the classical approach that assumes reversible mechanisms of inhibition are ubiquitous. 

The second important aspect lies in the delay time of inhibition, which is the time elapsed between the release of NE from die neutrophil and the formation of die enzyme-inhibitor complex. When elastase is released from neutrophils, three is a competition between foe substrate and the inhibitor for the binding Id the enzyme. The notion of delay time of inhibition was developed by Bieth [97,96], where he defined the delay time of inhibition, dt, as the time necessary to inhibit 99% of the enzyme activity. 

Many substances interact with enzymes to lower their activity that is, to inhibit them. Valuable information about the mechanism of action of the inhibitor can frequently be obtained through a kinetic analysis of its effects. To illustrate, let us consider a case of competitive inhibition, in which an inhibitor molecule, I, combines only with the free enzyme, E, but cannot combine with the enzyme to which the substrate is attached, ES. Such a competitive inhibitor often has a chemical structure similar to the substrate, but is not acted on by the enzyme. For example, malonate (-OOCCH2COO-) is a competitive inhibitor of succinate (-OOCCH2CH2COO-) dehydrogenase. If we use the same approach that was used in deriving the Michaelis-Menten equation together with the additional equilibrium that defines a new constant, an inhibitor constant, A),... 

The non-competitive and uncompetitive modes of inhibition described above are special cases that in practice arise very rarely in these simple forms. In reality, the situation is usually more complex in that inhibitors bind with differing affinities to the free and substrate-bound forms of the enzyme, and also the ternary EIS complex may be able to undergo catalysis, albeit at a lower rate. These circumstances define what is called mixed inhibition, which is less easy to characterise since the kinetic behaviour and equations are much more complex. The reader is referred to Cor-nish-Bowden (1995) for a comprehensive and authoritative account of this and other aspects of enzyme kinetics. 

Competitive inhibitors are so named because they compete for the active site with the native substrate, meaning that only enzyme-inhibitor or enzyme-substrate complex formation is possible (Fig. 7-3a). In this case, the inhibition constant, or enzyme-inhibitor complex dissociation constant, can be defined ... 

In this case, formation of El is a dead-end complex and the only way to generate catalytically active enzyme is for the reformation of E + I. Because competitive inhibition has no effect on Emax, a change (increase) in Aim must occur and thus this type of inhibition is characterized as an increase in ATn,. However, to assist in characterization of inhibitors it may be more straightforward and simpler to describe competitive inhibition as a decrease in Emax/ m with no change in the apparent En,ax- Thn equation for defining competitive inhibition is listed below as Equation 4.12. 

---